169 related articles for article (PubMed ID: 35082295)
41. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
[TBL] [Abstract][Full Text] [Related]
42. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
De Ramón C; Rojas EA; Cardona-Benavides IJ; Mateos MV; Corchete LA; Gutiérrez NC
Br J Haematol; 2022 Nov; 199(3):344-354. PubMed ID: 35983648
[TBL] [Abstract][Full Text] [Related]
43. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
44.
Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
[No Abstract] [Full Text] [Related]
45. Hierarchy of mono- and biallelic
Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
[No Abstract] [Full Text] [Related]
46. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
47. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
48. The level of deletion 17p and bi-allelic inactivation of
Thanendrarajan S; Tian E; Qu P; Mathur P; Schinke C; van Rhee F; Zangari M; Rasche L; Weinhold N; Alapat D; Bellamy W; Ashby C; Mattox S; Epstein J; Yaccoby S; Barlogie B; Hoering A; Bauer M; Walker BA; Davies FE; Morgan GJ
Haematologica; 2017 Sep; 102(9):e364-e367. PubMed ID: 28550191
[No Abstract] [Full Text] [Related]
49. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
50. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
[TBL] [Abstract][Full Text] [Related]
51. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
52. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
53. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
Zenz T; Kröber A; Scherer K; Häbe S; Bühler A; Benner A; Denzel T; Winkler D; Edelmann J; Schwänen C; Döhner H; Stilgenbauer S
Blood; 2008 Oct; 112(8):3322-9. PubMed ID: 18689542
[TBL] [Abstract][Full Text] [Related]
54.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
55. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
[TBL] [Abstract][Full Text] [Related]
56. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Chin M; Sive JI; Allen C; Roddie C; Chavda SJ; Smith D; Blombery P; Jones K; Ryland GL; Popat R; Rismani A; D'Sa S; Rabin N; Gale RE; Yong KL
Blood Cancer J; 2017 Sep; 7(9):e610. PubMed ID: 29016571
[No Abstract] [Full Text] [Related]
57. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
58. ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma.
Zhu G; Liao X; Han C; Liu X; Yu L; Qin W; Lu S; Su H; Chen Z; Liu Z; Liang Y; Huang J; Yu T; Yang C; Huang K; Shang L; Ye X; Li L; Qin X; Xiao K; Peng M; Peng T
Oncol Rep; 2017 Sep; 38(3):1451-1463. PubMed ID: 28714006
[TBL] [Abstract][Full Text] [Related]
59. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor.
Ishii N; Tada M; Hamou MF; Janzer RC; Meagher-Villemure K; Wiestler OD; Tribolet N; Van Meir EG
Oncogene; 1999 Oct; 18(43):5870-8. PubMed ID: 10557074
[TBL] [Abstract][Full Text] [Related]
60. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
